1/27/2020 4:03:07 PM
Acceleron Announces Sotatercept Achieved Primary And Secondary Endpoints In The PULSAR Phase 2 Placebo-Controlled Trial
1/23/2020 4:18:52 PM
Acceleron Pharma Says John Quisel, EVP And Chief Business Officer, Is Leaving Company
2/28/2018 7:56:52 AM
RBC Capital Markets Is Increasing Acceleron Pharma, Inc (XLRN) FY18 Rev. Estimate To 40.97 M From 39.40 M
2/28/2018 7:48:47 AM
RBC Capital Markets Is Cutting Acceleron Pharma, Inc (XLRN) FY18 Estimate To -2.83 From -2.73